title: [The obsessive compulsive disorder].
abstract: The obsessive compulsive disorder (OCD) is a frequent disease with a high comorbidity. The usual treatment is a combination of pharmacological and psychotherapeutic treatment. However, 30% of patients still have persistent and severe symptoms, with an important functional impact. These last years, the integration of the new neuroanatomical, neurochemical, neuropsychological, genetic and phenomenological data, allows a better understanding of the physiopathology and the development of new treatments for OCD, as neuromodulation for the severe and refractory cases.
authors.affiliation: Service de psychiatrie de liaison et intervention crise, hôpitaux universitaires de Genève (HUG), Genève, Suisse - Équipe BEBG (behavior, emotion and basal ganglia), Institut du cerveau et de la moelle épinière (ICM), hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France.
authors.forename: João
authors.initials: J
authors.lastname: Flores Alves Dos Santos
authors.affiliation: Équipe BEBG (behavior, emotion and basal ganglia), Institut du cerveau et de la moelle épinière (ICM), hôpital Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France - Fondation FondaMental, Hôpital Albert Chenevier, 94000 Créteil, France.
authors.forename: Luc
authors.initials: L
authors.lastname: Mallet
mesh_terms: D003131:Combined Modality Therapy; D015897:Comorbidity; D046690:Deep Brain Stimulation; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D030342:Genetic Diseases, Inborn; D006801:Humans; D018377:Neurotransmitter Agents; D009771:Obsessive-Compulsive Disorder / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D011613:Psychotherapy
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018377:Neurotransmitter Agents